GSK: agreement to acquire potential Lupus treatment
(CercleFinance.com) - GSK announces that it has reached an agreement with Chimagen Biosciences (Chimagen) - an unlisted biotechnology company - to acquire CMG1A46, a clinical-stage T-cell engaging agent (TCE) for an initial amount of $300m.
GSK plans to develop and commercialize CMG1A46 with a focus on B-cell-mediated autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with the possibility of expansion into related autoimmune diseases.
As a new therapeutic option, CMG1A46 offers exciting potential that we are pleased to bring to bear to address unmet needs in lupus and other related autoimmune conditions, GSK said.
GSK points out that CMG1A46 is currently in phase I clinical trials for leukemia and lymphoma in the USA and China. The company aims to launch a Phase I trial in lupus in 2025.
Under the terms of the agreement, GSK will pay $300m upfront to acquire full worldwide rights to CMG1A46. In addition, Chimagen will be eligible for milestone payments for the development and commercialization of CMG1A46, totaling $550m.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
GSK plans to develop and commercialize CMG1A46 with a focus on B-cell-mediated autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with the possibility of expansion into related autoimmune diseases.
As a new therapeutic option, CMG1A46 offers exciting potential that we are pleased to bring to bear to address unmet needs in lupus and other related autoimmune conditions, GSK said.
GSK points out that CMG1A46 is currently in phase I clinical trials for leukemia and lymphoma in the USA and China. The company aims to launch a Phase I trial in lupus in 2025.
Under the terms of the agreement, GSK will pay $300m upfront to acquire full worldwide rights to CMG1A46. In addition, Chimagen will be eligible for milestone payments for the development and commercialization of CMG1A46, totaling $550m.
Copyright (c) 2024 CercleFinance.com. All rights reserved.